Stem Cell Therapeutics Announces Issuance of Additional US Patent for Use of Prolactin

CALGARY, ALBERTA, May 19 (MARKET WIRE) --
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) has been issued
United States Patent No. 7,534,765, entitled "Pregnancy Induced
Oligodendrocyte Precursor Cell Proliferation Regulated by Prolactin".
This patent, issued today, covers methods of using of prolactin for
enhancing the formation of oligodendendrocytes in vivo, such as to treat
diseases associated with loss of myelin-producing oligodendrocytes (white
matter diseases).

Dr. Alan Moore, President and CEO, commented as
follows:

"This patent bolsters our intellectual property position around the use
of prolactin for treating demyelinating neurodegenerative diseases such
as multiple sclerosis ("MS") in which the myelin sheath surrounding the
axon of neurons is damaged. The finding that prolactin enhances
oligodendrocyte production and remyelination is what stimulated the
development of our NTx(R)-488 program for MS, with preclinical studies
being completed in preparation for Phase II clinical trials.

Importantly, as covered by other SCT patents, prolactin also stimulates
neural stem cell proliferation and neurogenesis. Prolactin is therefore
expected to repair both the myelin damage and the neuronal damage in MS,
which is necessary for full functional recovery, and makes prolactin a
unique MS drug candidate."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a
Canadian public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development of
therapies that utilize drugs to stimulate a patient's own resident stem
cells. The Company's programs aim to repair neurological function lost
due to disease or injury. The Company's extensive patent portfolio of
owned and licensed intellectual property supports the potential expansion
into future clinical programs in numerous neurological diseases such as
traumatic brain injury, multiple sclerosis Huntington's disease,
Alzheimer's disease, and ALS.

These securities have not been registered under the United States
Securities Act of 1933, as amended, or the securities laws of any state,
and may not be offered or sold within the United States or to, or for the
account or benefit of U.S. persons unless an applicable exemption from
U.S. registration requirements is available.

Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause but are not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.

Contacts:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
(403) 245-5495 ext.224
Email: amoore@stemcellthera.com

Stem Cell Therapeutics Corp.
Chloe Douglas-Crampton
Investor Relations
(403) 245-5495 ext. 221
Email: crampton@stemcellthera.com
Website: www.stemcellthera.com

Copyright 2009, Market Wire, All rights reserved.

-0-